Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania (Q46650874)

From Wikidata

Jump to navigation Jump to search

scientific article published in January 2005

Language	Label	Description	Also known as
English	Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania	scientific article published in January 2005

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100941

Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100941

expanded access

1 reference

based on heuristic

inferred from title

author name string

Maria Luisa Veronese

1

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100941

Kenneth Algazy

2

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100941

Lisa Bearn

3

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100941

Beth Eaby

4

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100941

Jane Alavi

5

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100941

Tracey Evans

6

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100941

James P Stevenson

7

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100941

Justine Shults

8

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100941

publication date

1 January 2005

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100941

Cancer Investigation

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100941

23

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100941

4

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100941

296-302

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100941

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1081%2FCNV-61528

21 January 2018

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1081%2FCNV-61528

21 January 2018

Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group

1 reference

https://api.crossref.org/works/10.1081%2FCNV-61528

21 January 2018

Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.

1 reference

https://api.crossref.org/works/10.1081%2FCNV-61528

21 January 2018

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

1 reference

https://api.crossref.org/works/10.1081%2FCNV-61528

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1081%2FCNV-61528

21 January 2018

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1081%2FCNV-61528

21 January 2018

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1081%2FCNV-61528

21 January 2018

Cell signaling by receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1081%2FCNV-61528

21 January 2018

EGFR and cancer prognosis

1 reference

https://api.crossref.org/works/10.1081%2FCNV-61528

21 January 2018

The epidermal growth factor receptor and its inhibition in cancer therapy

1 reference

https://api.crossref.org/works/10.1081%2FCNV-61528

21 January 2018

Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas

1 reference

https://api.crossref.org/works/10.1081%2FCNV-61528

21 January 2018

Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

1 reference

https://api.crossref.org/works/10.1081%2FCNV-61528

21 January 2018

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

1 reference

https://api.crossref.org/works/10.1081%2FCNV-61528

21 January 2018

United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets

1 reference

https://api.crossref.org/works/10.1081%2FCNV-61528

21 January 2018

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

1 reference

https://api.crossref.org/works/10.1081%2FCNV-61528

21 January 2018

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1081%2FCNV-61528

21 January 2018

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1081%2FCNV-61528

21 January 2018

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1081%2FCNV-61528

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1081%2FCNV-61528

21 January 2018

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1081%2FCNV-61528

21 January 2018

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1081%2FCNV-61528

21 January 2018

ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program

1 reference

https://api.crossref.org/works/10.1081%2FCNV-61528

21 January 2018

Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.

1 reference

https://api.crossref.org/works/10.1081%2FCNV-61528

21 January 2018

Gefitinib in the Treatment of Advanced, Refractory Non–Small-Cell Lung Cancer: Results in 124 Patients

1 reference

https://api.crossref.org/works/10.1081%2FCNV-61528

21 January 2018

Developing inhibitors of the epidermal growth factor receptor for cancer treatment.

1 reference

https://api.crossref.org/works/10.1081%2FCNV-61528

21 January 2018

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1081%2FCNV-61528

21 January 2018

Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1081%2FCNV-61528

21 January 2018

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1081%2FCNV-61528

21 January 2018

Identifiers

10.1081/CNV-61528

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100941

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16100941

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46650874&oldid=2124300133"